Anti-Cd274/PD-L1 antibody [10F.9G2] {Biotin} (STJA0001822)
SPECIFICATIONS
ClonalityMonoclonal
HostRat
ConjugationBiotin
IsotypeIgG2bk
General Information
| Short Description | Rat monoclonal anti-Programmed cell death 1 ligand 1 for use in FC in Mouse samples. Datasheet included with dilution recommendations, and related reagents. |
| Applications | FC |
| Host | Rat |
| Reactivity | Mouse |
| Note | FOR SCIENTIFIC EDUCATIONAL RESEARCH USE ONLY (RUO). MUST NOT BE USED IN DIAGNOSTIC OR OTHER MEDICAL APPLICATIONS. |
Product Properties
| Clonality | Monoclonal |
| Clone ID | 10F.9G2 |
| Isotype | IgG2bk |
| Conjugation | Biotin |
| Concentration | 0.5 mg/mL |
| Formulation | Phosphate buffered solution, pH 7.2, containing 0.09% stabilizer and 1% protein protectant. |
| Storage Instruction | This product can be stored at 2-8ยฐC for 12 months. Do not freeze. |
Target Information
| Gene Symbol | Cd274 |
| Gene ID | 60533 |
| Uniprot ID | PD1L1_MOUSE |
Additional Info
| Tissue Specificity | Highly expressed in the heart, thymus, skeletal muscle, and lung. Weakly expressed in the kidney, spleen, thyroid, and liver. Expressed on activated dendritic cells, B-cells and macrophages. Expressed in numerous tumor cells lines of lymphoid origin. |
| Post Translational Modifications | Ubiquitinated.STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation. Ubiquitinated by MARCHF8.leading to degradation. Deubiquitinated by USP22.leading to stabilization. |
| Function | Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy. |
| Protein Name | Programmed Cell Death 1 Ligand 1Pd-L1Pdcd1 Ligand 1Programmed Death Ligand 1B7 Homolog 1B7-H1Cd Antigen Cd274 |
| Database Links | Reactome: R-MMU-389948 |
| Cellular Localisation | Cell MembraneSingle-Pass Type I Membrane ProteinEarly Endosome MembraneRecycling Endosome Membrane |
| Alternative Antibody Names | Anti-Programmed Cell Death 1 Ligand 1 antibodyAnti-Pd-L1 antibodyAnti-Pdcd1 Ligand 1 antibodyAnti-Programmed Death Ligand 1 antibodyAnti-B7 Homolog 1 antibodyAnti-B7-H1 antibodyAnti-Cd Antigen Cd274 antibodyAnti-Cd274 antibodyAnti-B7h1 antibodyAnti-Pdcd1l1 antibodyAnti-Pdcd1lg1 antibodyAnti-Pdl1 antibody |
Information sourced from Uniprot.org